Home > Riviste > Panminerva Medica > Fascicoli precedenti > Panminerva Medica 1998 September;40(3) > Panminerva Medica 1998 September;40(3):186-90

ULTIMO FASCICOLO
 

JOURNAL TOOLS

eTOC
Per abbonarsi PROMO
Sottometti un articolo
Segnala alla tua biblioteca
 

ARTICLE TOOLS

Estratti
Permessi

 

ORIGINAL ARTICLES   

Panminerva Medica 1998 September;40(3):186-90

Copyright © 2000 EDIZIONI MINERVA MEDICA

lingua: Inglese

Study of release of eosinophil cationic proteins (ECP and EPX) in the hypereosinophilic syndrome (HES) and other hypereosinophilic conditions

Bobbio-Pallavicini E.*, Confalonieri M.**, Tacconi F.*, Mainardi E.*, Della Porta R.***, Ceccato D.°, Maccario R.°, De Amici M.°

From the * Division of General Medicine and ** Division of Pneumology Ospedale Maggiore, Crema ***Division of General Medicine Cortemaggiore Hospital °Institute of Pediatric Clinic, IRCCS San Matteo Polyclinic University of Pavia, Pavia, Italy


PDF


Back­ground. Up to ­date, the eti­ol­o­gy and the path­o­gen­e­sis of HES are ­still ­unknown and par­tic­u­lar­ly it is ­unclear why eosin­o­phils in HES are ­more aggres­sive ­towards tis­sues ­than in oth­er eosin­o­phil­ic con­di­tions.
Meth­ods. We ­assessed the cat­ion­ic pro­teins ECP and EPX ser­um con­cen­tra­tions, ­their in ­vitro ­release ­from poly­mor­pho­nu­cle­ar ­cell cul­ture, and the mono­clo­nal anti­bod­ies EG1 and EG2 in 3 ­patients ­with HES, 6 ­patients ­with oth­er hyper­eo­sin­o­phil­ic con­di­tions and 20 ­healthy con­trol sub­jects.
­Results. Ser­um ECP and EPX con­cen­tra­tions ­were high­er in eosin­o­phil­ic ­patients ­than in ­healthy sub­jects. Hyper­eo­sin­o­phil­ic ­patients had ­more EG2+ ­cells ­than ­healthy sub­jects, but EG2+ ­rate ­failed to dif­fer­en­tiate HES ­from oth­er hyper­eo­sin­o­phil­ic con­di­tions (p=0.074). More­over, the ­release in ­vitro of ECP and EPX was sig­nif­i­cant­ly high­er in HES ­patients (p<0.05).
Con­clu­sions. Our pre­lim­i­nary ­results ­seem to sug­gest the impor­tance of func­tion­al ­data, ­such as ECP and EPX ­release, in dif­fer­en­tiat­ing HES ­from oth­er hyper­eo­sin­o­phil­ic dis­eas­es. Par­tic­u­lar­ly, ECP and EPX ­release in ­vitro is high­er in ­cell cul­tures ­from HES ­patients ­than ­from ­patients ­with oth­er hyper­eo­sin­o­phil­ic con­di­tions.

inizio pagina